Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Biology and therapeutic targeting of molecular mechanisms in MPNs

Blood(2022)10.1182/blood.2022017416Source: DataRank Database

Biology and therapeutic targeting of molecular mechanisms in MPNs is a research paper published in Blood (2022). On theSindex it has a DataRank of 0. It has been cited 67 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access67 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 8.19)OA: hybridTopics (44)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Jacqueline S. Garcia ORCID,Ann Mullally ORCID,Joan How ORCID

Live enrichment

PubMed:36534936 PMC:PMC10163317 OpenAlex:https://openalex.org/W4312019091

NHLBI NIH HHS

Grant: R01 HL131835

NCI NIH HHS

Grant: K08 CA245209

National Institutes of Health

Grant: 5K08CA245209-03

Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia

National Institutes of Health

Grant: 5R01HL131835-03

Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms

FWCI

8.19

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://ashpublications.org/blood/article-pdf/141/16/1922/2045345/blood_bld-2022-017416-c-main.pdf

publisherhttps://ashpublications.org/blood/article-pdf/141/16/1922/2045345/blood_bld-2022-017416-c-main.pdf

publisherhttps://ashpublications.org/blood/article-pdf/141/16/1922/2087811/blood_bld-2022-017416-c-main.pdf

journalhttps://doi.org/10.1182/blood.2022017416

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36534936

Fields of Study

Myeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesAcute Myeloid Leukemia Research03 medical and health sciences0302 clinical medicine

MeSH Terms

Janus Kinase InhibitorsBiologyHumansMutationMyeloproliferative DisordersPolycythemia VeraDisease ProgressionJanus KinasesJanus Kinase 2Primary MyelofibrosisTumor Microenvironment

Keywords

Janus kinaseEssential thrombocythemiaRuxolitinibPolycythemia veraMyelofibrosisStem cellMedicineJanus kinase 2HaematopoiesisImmunologyThrombocytosisCancer researchBiologyBone marrowBioinformaticsInternal medicinePlateletReceptorCytokineClassic Myeloproliferative NeoplasmsMyeloproliferative DisordersPrimary MyelofibrosisMutationDisease ProgressionTumor MicroenvironmentHumansJanus Kinase InhibitorsJanus Kinases

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Biology and therapeutic targeting of molecular mechanisms in MPNs

FAIR Checklist

Authors (3)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)